Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1988 14
1989 18
1990 12
1991 14
1992 14
1993 14
1994 24
1995 25
1996 27
1997 20
1998 28
1999 41
2000 45
2001 51
2002 64
2003 51
2004 67
2005 58
2006 76
2007 67
2008 83
2009 96
2010 124
2011 115
2012 121
2013 135
2014 223
2015 282
2016 304
2017 344
2018 316
2019 378
2020 398
2021 385
2022 423
2023 391
2024 378
2025 196

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,803 results

Results by year

Filters applied: . Clear all
Page 1
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R. Gradishar WJ, et al. J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035. J Natl Compr Canc Netw. 2024. PMID: 39019058
Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical …
Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncolo …
Breast cancer in adolescents and young adults.
Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A. Johnson RH, et al. Pediatr Blood Cancer. 2018 Dec;65(12):e27397. doi: 10.1002/pbc.27397. Epub 2018 Aug 28. Pediatr Blood Cancer. 2018. PMID: 30156052 Free PMC article. Review.
Breast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In comparison with older women, AYAs are more likely to have familial cancer …
Breast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for …
Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches.
Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L. Raheem F, et al. Int J Mol Sci. 2023 Nov 11;24(22):16198. doi: 10.3390/ijms242216198. Int J Mol Sci. 2023. PMID: 38003387 Free PMC article. Review.
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective as the disease progresses. ...In this article, we review the mechanisms of acquired …
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. However, advanced tumors develop re …
Pathology of breast cancer in the last half century.
Solanki M, Visscher D. Solanki M, et al. Hum Pathol. 2020 Jan;95:137-148. doi: 10.1016/j.humpath.2019.09.007. Epub 2019 Nov 1. Hum Pathol. 2020. PMID: 31682887 Review.
Pathologists, with the support of epidemiologists, have lead significant advancements in the description and clinical significance of benign breast disease. Despite considerable efforts, the cure for breast cancer awaits better understanding of the pathophysi …
Pathologists, with the support of epidemiologists, have lead significant advancements in the description and clinical significance of benign …
Second Primary Breast Cancer in Young Breast Cancer Survivors.
Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Warner E, Come SE, Zheng Y, Kirkner GJ, Snow C, Winer EP, Partridge AH. Brantley KD, et al. JAMA Oncol. 2024 Jun 1;10(6):718-725. doi: 10.1001/jamaoncol.2024.0286. JAMA Oncol. 2024. PMID: 38602683 Free PMC article.
IMPORTANCE: Among women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher than that of women who are older when they develop a first primary BC. ...DESIGN, SETTING, A …
IMPORTANCE: Among women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that the …
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM; Exceptional Responders Clinical Trials Group. Kuerer HM, et al. Lancet Oncol. 2022 Dec;23(12):1517-1524. doi: 10.1016/S1470-2045(22)00613-1. Epub 2022 Oct 25. Lancet Oncol. 2022. PMID: 36306810 Clinical Trial.
BACKGROUND: Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and HER2-positive breast cancer yields a pathological complete response in approximately 60% of patients. ...We evaluated radiotherapy alone, without breast surgery …
BACKGROUND: Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and HER2-positive breast cancer …
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK; Alliance for Clinical Trials in Oncology. Boughey JC, et al. JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932. JAMA. 2013. PMID: 24101169 Free PMC article. Clinical Trial.
IMPORTANCE: Sentinel lymph node (SLN) surgery provides reliable nodal staging information with less morbidity than axillary lymph node dissection (ALND) for patients with clinically node-negative (cN0) breast cancer. The application of SLN surgery for staging the ax …
IMPORTANCE: Sentinel lymph node (SLN) surgery provides reliable nodal staging information with less morbidity than axillary lymph node disse …
Trajectories of fear of cancer recurrence in young breast cancer survivors.
Schapira L, Zheng Y, Gelber SI, Poorvu P, Ruddy KJ, Tamimi RM, Peppercorn J, Come SE, Borges VF, Partridge AH, Rosenberg SM. Schapira L, et al. Cancer. 2022 Jan 15;128(2):335-343. doi: 10.1002/cncr.33921. Epub 2021 Oct 6. Cancer. 2022. PMID: 34614212 Free PMC article.
METHODS: A total of 965 women with stage 0 to stage III breast cancer enrolled in the Young Women's Breast Cancer Study, a prospective cohort of women diagnosed with breast cancer at age 40 years, completed the 3-item Lasry Fear of Recurr …
METHODS: A total of 965 women with stage 0 to stage III breast cancer enrolled in the Young Women's Breast Cancer …
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. Gradishar WJ, et al. J Natl Compr Canc Netw. 2020 Apr;18(4):452-478. doi: 10.6004/jnccn.2020.0016. J Natl Compr Canc Netw. 2020. PMID: 32259783
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-re …
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to impro …
[Oncogenetics].
Suerink M, Bleiker EMA, Nielsen M, Houwink EJF, Baas JM, Ausems MGEM. Suerink M, et al. Ned Tijdschr Geneeskd. 2022 Dec 22;167:D6958. Ned Tijdschr Geneeskd. 2022. PMID: 36633037 Dutch.
Determining whether a hereditary cancer predisposition is present, is important for both the cancer patient and his family. ...The consequences of a genetic diagnosis are illustrated by a breast cancer case....
Determining whether a hereditary cancer predisposition is present, is important for both the cancer patient and his family. .. …
4,803 results